October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 13, 2025

First Alzheimer's Test for Primary Care

Roche’s FDA-cleared Elecsys pTau181 blood test helps physicians rule out Alzheimer’s pathology early and streamline diagnosis.

Conexiant

October 10, 2025

FDA Broadens Label for Schizophrenia Drug

The FDA has approved a new long-acting injectable treatment option for adults with bipolar I disorder.

Conexiant

October 07, 2025

FDA Announces New Development in Lung Care

The FDA has approved the first treatment in more than a decade for idiopathic pulmonary fibrosis.

Conexiant

October 03, 2025

FDA Sets Science Agenda for Generics: Priorities for 2026

The FDA has unveiled its top science and research priorities for FY 2026 under the GDUFA program, including nitrosamine risk, complex drug development, bioequivalence innovations, and the use of AI and modeling to modernize generics regulation.

The Medicine Maker

October 03, 2025

From Agent Orange to PCBs: Lessons for Care

Air Force reviews cancer risk in missile crews; early analyses show no excess mortality, but exposures to PCBs and benzene prompt vigilance and targeted histories.

KFF Health News

October 02, 2025

FDA Removes Vandetanib REMS Program

On September 25, the U.S. Food and Drug Administration (FDA) removed the Risk Evaluation and Mitigation Strategies (REMS) program for vandetanib, according to an announcement from the agency. 

The ASCO Post

October 01, 2025

Shutdown Showdown: How Long Can Health Services Last?

Federal shutdown suspends some health services, limits National Institutes of Health research, and raises questions about Affordable Care Act subsidies, Medicaid, and public health programs.

KFF Health News

October 01, 2025

How Safe Are FDA-Cleared AI Tools?

“These findings indicate that standardized efficacy, safety, and risk assessment reporting remains inadequate for FDA-cleared AI/ML devices, underscoring the need for dedicated regulatory pathways and robust postmarket surveillance to ensure patient safety."

Conexiant